

# Long-term Follow-up of Study Participants Who Received an Allo-geneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study

NCT05822427

---

**Status** RECRUITING  
**Sponsor** Imugene Limited  
**Enrollment** 75 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Receipt of at least 1 dose of azer-cel in an Imugene clinical study.
- A signed informed consent form (ICF).
- Willingness and ability to adhere to the study schedule and all other protocol requirements.

## Locations (1 total)

---

Science 37, Inc., Culver City, California, United States